These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 28393731)

  • 1. Moxifloxacin related thrombocytopeniae: A case report.
    Çörtük M; Benli AR; Köroğlu M; Yazıcı O; Acat M; Casim H; Çetinkaya E
    Tuberk Toraks; 2016 Sep; 64(3):250-252. PubMed ID: 28393731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-induced immune thrombocytopenia due to moxifloxacin.
    Coker TJ
    BMJ Case Rep; 2013 Jan; 2013():. PubMed ID: 23329709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Syndrome of inappropriate antidiuretic hormone associated with moxifloxacin.
    Yam FK; Eraly SA
    Am J Health Syst Pharm; 2012 Feb; 69(3):217-20. PubMed ID: 22261943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe corneal toxicity after topical fluoroquinolone therapy: report of two cases.
    Walter K; Tyler ME
    Cornea; 2006 Aug; 25(7):855-7. PubMed ID: 17068466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moxifloxacin-associated neutropenia in a cirrhotic elderly woman with lower extremity cellulitis.
    Chang CM; Lee NY; Lee HC; Lee IW; Wu CJ; Lin YS; Ko WC
    Ann Pharmacother; 2008 Apr; 42(4):580-3. PubMed ID: 18349304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orofacial dyskinesia after moxifloxacin treatment--a case with normal hepatorenal function and review of literature.
    Mittal SO; Machado DG; Jabbari B
    Clin Neuropharmacol; 2012; 35(6):292-4. PubMed ID: 23151468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moxifloxacin-induced QT prolongation and torsades: an uncommon effect of a common drug.
    Badshah A; Janjua M; Younas F; Halabi AR; Cotant JF
    Am J Med Sci; 2009 Aug; 338(2):164-6. PubMed ID: 19680025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia.
    Friedman H; Song X; Crespi S; Navaratnam P
    Value Health; 2009; 12(8):1135-43. PubMed ID: 19695010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens.
    Hoeffken G; Talan D; Larsen LS; Peloquin S; Choudhri SH; Haverstock D; Jackson P; Church D
    Eur J Clin Microbiol Infect Dis; 2004 Oct; 23(10):772-5. PubMed ID: 15605184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial.
    Ruslami R; Ganiem AR; Dian S; Apriani L; Achmad TH; van der Ven AJ; Borm G; Aarnoutse RE; van Crevel R
    Lancet Infect Dis; 2013 Jan; 13(1):27-35. PubMed ID: 23103177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moxifloxacin: new indication. Inadequate restriction of indications in ENT and respiratory infections.
    Prescrire Int; 2009 Oct; 18(103):206. PubMed ID: 19882787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effects of fourth-generation fluoroquinolones on epithelial healing after photorefractive keratectomy.
    Shin JH; Lee HB; Park HY
    Cornea; 2010 Nov; 29(11):1236-40. PubMed ID: 20697276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA Study).
    Weiss G; Reimnitz P; Hampel B; Muehlhofer E; Lippert H;
    J Chemother; 2009 Apr; 21(2):170-80. PubMed ID: 19423470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moxifloxacin associated vanishing bile duct syndrome.
    Robinson W; Habr F; Manlolo J; Bhattacharya B
    J Clin Gastroenterol; 2010 Jan; 44(1):72-3. PubMed ID: 19581811
    [No Abstract]   [Full Text] [Related]  

  • 15. The use of moxifloxacin for acute exacerbations of chronic obstructive pulmonary disease and chronic bronchitis.
    Wilson R; Macklin-Doherty A
    Expert Rev Respir Med; 2012 Nov; 6(5):481-92. PubMed ID: 23113693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
    McDonald MB; Protzko EE; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL; Usner DW
    Ophthalmology; 2009 Sep; 116(9):1615-1623.e1. PubMed ID: 19643483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moxifloxacin: new indication. Do not use in gynaecological infections or other conditions.
    Prescrire Int; 2009 Oct; 18(103):207. PubMed ID: 19882788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zabofloxacin versus moxifloxacin in patients with COPD exacerbation: a multicenter, double-blind, double-dummy, randomized, controlled, Phase III, non-inferiority trial.
    Rhee CK; Chang JH; Choi EG; Kim HK; Kwon YS; Kyung SY; Lee JH; Park MJ; Yoo KH; Oh YM
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2265-75. PubMed ID: 26543359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moxifloxacin five-day therapy versus placebo in acute bacterial rhinosinusitis.
    Hadley JA; Mösges R; Desrosiers M; Haverstock D; van Veenhuyzen D; Herman-Gnjidic Z
    Laryngoscope; 2010 May; 120(5):1057-62. PubMed ID: 20422704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe pseudomembranous colitis after moxifloxacin use: a case series.
    Gallagher JC; Du JK; Rose C
    Ann Pharmacother; 2009 Jan; 43(1):123-8. PubMed ID: 19066322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.